Carfilzomib preserves dendritic cell phenotype and function compared with bortezomib. (PubMed, Front Immunol) - Oct 8, 2026 - "PD-1 blockade with nivolumab fully reversed this effect and significantly enhanced it in MLR. Our findings show that carfilzomib does not cause the broad impairment seen with bortezomib, and that the discrete deficit it does produce is reversible with PD-1 blockade. We hypothesize that carfilzomib is a more suitable proteasome inhibitor partner for DC-based immunotherapeutic strategies."
Clinical • IO biomarker • Journal • Hematological Malignancies • Multiple Myeloma • Oncology • IFNG • PD-L1
|
|
D Dörfel; F Grünebach; J S Walz; L Wang; M Dahlfrancis; M G Klatt; S M Rittig
|